TWI786132B - 活性抑制劑於發炎性疾病之治療 - Google Patents

活性抑制劑於發炎性疾病之治療 Download PDF

Info

Publication number
TWI786132B
TWI786132B TW107120362A TW107120362A TWI786132B TW I786132 B TWI786132 B TW I786132B TW 107120362 A TW107120362 A TW 107120362A TW 107120362 A TW107120362 A TW 107120362A TW I786132 B TWI786132 B TW I786132B
Authority
TW
Taiwan
Prior art keywords
antibody
amino acid
binding
human
ifx
Prior art date
Application number
TW107120362A
Other languages
English (en)
Chinese (zh)
Other versions
TW201904611A (zh
Inventor
郭仁峰
尼爾斯 萊德曼
Original Assignee
德商因夫萊亞斯有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商因夫萊亞斯有限公司 filed Critical 德商因夫萊亞斯有限公司
Publication of TW201904611A publication Critical patent/TW201904611A/zh
Application granted granted Critical
Publication of TWI786132B publication Critical patent/TWI786132B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
TW107120362A 2017-06-23 2018-06-13 活性抑制劑於發炎性疾病之治療 TWI786132B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP17177657.8 2017-06-23
??17177657.8 2017-06-23
EP17177657 2017-06-23
??17189938.8 2017-09-07
EP17189938.8 2017-09-07
EP17189938 2017-09-07

Publications (2)

Publication Number Publication Date
TW201904611A TW201904611A (zh) 2019-02-01
TWI786132B true TWI786132B (zh) 2022-12-11

Family

ID=62636193

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107120362A TWI786132B (zh) 2017-06-23 2018-06-13 活性抑制劑於發炎性疾病之治療

Country Status (10)

Country Link
EP (1) EP3642230A1 (https=)
JP (1) JP7502865B2 (https=)
KR (1) KR20200020727A (https=)
CN (1) CN111201241A (https=)
AU (1) AU2018286754A1 (https=)
CA (1) CA3066689C (https=)
IL (1) IL271074A (https=)
SG (1) SG11201912882QA (https=)
TW (1) TWI786132B (https=)
WO (1) WO2018234118A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
MA55285A (fr) * 2019-03-14 2022-01-19 Morphosys Ag Anticorps ciblant c5ar
TWI869528B (zh) * 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
EP4126222A1 (en) * 2020-03-27 2023-02-08 InflaRx GmbH Inhibitors of c5a for the treatment of corona virus infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
EP4172200A4 (en) 2020-06-24 2024-10-30 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTIBODIES SPECIFICALLY RECOGNIZING C5A AND THEIR USES
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
PL3385384T3 (pl) 2004-02-12 2021-03-08 Archemix Llc Aptamerowe środki terapeutyczne użyteczne w leczeniu zaburzeń powiązanych z dopełniaczem
AU2005226792A1 (en) * 2004-03-26 2005-10-06 Promics Pty Limited Treatment of neurological conditions using complement C5a receptor modulators
EP2049141A4 (en) 2006-07-21 2011-10-26 Promics Pty Ltd TREATMENT OF INTIMAL HYPERPLASIA AND ASSOCIATED DISEASES
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
CA2965223C (en) 2008-12-22 2019-09-24 Chemocentryx, Inc. C5ar antagonists
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
PT2585064T (pt) 2010-06-24 2017-08-08 Chemocentryx Inc Antagonistas do c5ar
CA3216595A1 (en) 2013-03-14 2014-10-02 Kevin Fitzgerald Complement component c5 irna compositions and methods of use thereof
CN105392803B (zh) * 2013-05-08 2019-12-06 诺和诺德股份有限公司 C5aR拮抗剂的用途
EP3119802B1 (en) * 2014-03-20 2019-12-04 InflaRx GmbH Inhibitors of c5a for the treatment of viral pneumonia
WO2016044419A1 (en) 2014-09-16 2016-03-24 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016061066A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
FR3030515B1 (fr) * 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
EP3313437A1 (en) 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
AU2017246228B2 (en) 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
期刊 Angela M. Finch,et al. "Low-Molecular-Weight Peptidic and Cyclic Antagonists of the Receptor for the Complement Factor C5a", J. Med. Chem. 1999, 42, 965-1974 *
期刊 E. Giamarellos-Bourboulis,et al. "Complement activation in hidradenitis suppurativa", Abstract - 2017 - Oral Presentation,Case O03-2, Experimental Dermatology , First published: 07 February 2017; *
期刊 Pirow Bekker et al, "Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study" , Plos One, 2016, Vol 11, pages 1-19.; *
網路文獻 inFlaRx, "InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anticomplementC5a antibody, in patients with Hidradenitis Suppurativa" 網址：https://uk.finance.yahoo.com/news/inflarxinitiatesexploratory- phase-ii-133001314.html, 2017年4月4日.; *

Also Published As

Publication number Publication date
SG11201912882QA (en) 2020-01-30
EP3642230A1 (en) 2020-04-29
CA3066689A1 (en) 2018-12-27
IL271074A (en) 2020-01-30
AU2018286754A1 (en) 2019-12-19
KR20200020727A (ko) 2020-02-26
JP7502865B2 (ja) 2024-06-19
TW201904611A (zh) 2019-02-01
WO2018234118A1 (en) 2018-12-27
JP2020524696A (ja) 2020-08-20
CN111201241A (zh) 2020-05-26
CA3066689C (en) 2024-01-16

Similar Documents

Publication Publication Date Title
US11890349B2 (en) Treatment of inflammatory diseases with inhibitors of C5A activity
US11273225B2 (en) Treatment of inflammatory diseases with inhibitors of C5a activity
TWI786132B (zh) 活性抑制劑於發炎性疾病之治療
CN107638565B (zh) 用于治疗与masp-2依赖性补体活化相关的状况的方法
KR20150031298A (ko) 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
RS61351B1 (sr) Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
TW201920288A (zh) 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
CN116390758A (zh) 用于治疗冠状病毒感染的C5a抑制剂
HK40101423A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
HK40070841A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
CA3159152A1 (en) Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplan
EA043076B1 (ru) Лечение воспалительных заболеваний с помощью ингибиторов активности c5a
HK40000612B (en) Treatment of inflammatory diseases with inhibitors of c5a activity
EA046178B1 (ru) Способы лечения и/или предотвращения реакции трансплантат против хозяина и/или диффузного альвеолярного кровотечения, и/или веноокклюзионной болезни, связанных с трансплантатом гемопоэтических стволовых клеток